T1	Participants 234 342	patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial
T2	Participants 365 525	The international non-inferiority trial enrolled women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies
#1	AnnotatorNotes T2	Participants were those in this trial.
T3	Participants 886 936	259 very platinum-sensitive patients were included
